Table 3.
Sleep-disordered breathing parameters of participants after 6 days of placebo vs. mirtazapine treatment
| Placebo | Mirtazapine | |
|---|---|---|
| TRT, min | 247.0 ± 138.6 | 187.0 ± 65.3 |
| TST, min | 201.5 ± 124.2 | 148.8 ± 58.1 |
| Sleep efficiency, % | 81.3 ± 15.0 | 79.2 ± 14.6 |
| Sleep inset latency, min | 11.4 ± 19.6 | 5.7 ± 9.1 |
| N1 sleep time, % sleep time | 47.5 ± 17.5 | 58.4 ± 20.1 |
| N2 sleep time, % sleep time | 46.4 ± 20.1 | 30.0 ± 17.1 |
| N3 sleep time, % sleep time | 1.4 ± 4.2 | 2.6 ± 7.4 |
| REM sleep time, % sleep time | 4.8 ± 5.3 | 9.0 ± 11.5 |
| Arousal index, arousals/h | 51.5 ± 20.9 | 53.0 ± 17.7 |
| AHI, events/h | 47.8 ± 20.6 | 46.4 ± 22.5 |
| OAI, apneas/h | 14.1 ± 18.8 | 12.8 ± 15.7 |
| CAI, apneas/h | 4.8 ± 8.3 | 3.5 ± 5.5 |
| ODI, desaturations/h | 18.3 ± 17.9 | 21.2 ± 20.6 |
Values are presented as means ± SD; n = 10 participants. AHI, apnea-hypopnea index; CAI, central apnea index; OAI, obstructive apnea index; ODI, oxygen desaturation index; REM, rapid eye movement; TRT, total recording time; TST, total sleep time.